FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999631457> ?p ?o ?g. }

• W2999631457 endingPage "106864" @default.
• W2999631457 startingPage "106864" @default.
• W2999631457 abstract "ObjectiveThe objective of this analysis was to provide a comprehensive analysis of safety data for adjunctive brivaracetam (BRV), an antiepileptic drug (AED) of the racetam class, for treatment of focal seizures in patients with epilepsy.MethodsData were pooled from two phase II, placebo-controlled, double-blind, dose-ranging trials (N01114 [ClinicalTrials.gov: NCT00175929], N01193 [NCT00175825]) and three phase III, placebo-controlled, double-blind, 12-week trials (N01252 [NCT00490035], N01253 [NCT00464269], and N01358 [NCT01261325]) in patients aged ≥16 years with focal seizures, as well as a phase III, placebo-controlled, double-blind, 16-week trial in patients aged ≥16 years with focal or generalized epilepsy (N01254 [NCT00504881]). Data are presented for the approved therapeutic dose range of 50–200 mg/day. Data for BRV administered intravenously (25–150 mg doses) were pooled separately from one phase III trial (N01258 NCT01405508]) and two clinical pharmacology trials (N01256 [Part B] [UCB Pharma, data on file]; EP0007 [NCT01796899]). Adverse events (AEs) of interest were summarized in relevant categories.ResultsThe safety pool comprised 1957 patients: 1271 receiving adjunctive BRV and 686 receiving placebo. Overall, the incidence of treatment-emergent adverse events (TEAEs) was 66.9% with BRV versus 62.8% with placebo. The most frequently reported TEAEs with BRV (≥5% of patients) versus placebo were somnolence (13.3% vs. 7.9%), headache (10.5% vs. 11.5%), dizziness (10.0% vs. 7.0%), and fatigue (8.2% vs. 4.2%). Incidence of psychiatric disorder-related TEAEs was 11.3% with BRV versus 8.2% with placebo. Behavioral disorder-related TEAE incidence was low (4.0% with BRV vs. 2.5% with placebo). Irritability was reported in 2.7% of BRV-treated patients vs. 1.5% of patients receiving placebo; anger, aggression, and agitation were each reported by ≤1% of patients receiving BRV. Treatment-emergent adverse events potentially associated with psychosis were psychotic disorder (three patients on BRV vs. two patients on placebo), auditory hallucination, illusion, visual hallucination (one patient each on BRV), epileptic psychosis, and hallucination (one patient each on placebo). No additional safety concerns were identified in patients with intravenous (IV) BRV administration (n = 104).ConclusionsThese safety data for adjunctive BRV support its acceptable safety and tolerability profile." @default.
• W2999631457 created "2020-01-23" @default.
• W2999631457 creator A5012345968 @default.
• W2999631457 creator A5027558784 @default.
• W2999631457 creator A5030901765 @default.
• W2999631457 creator A5059712623 @default.
• W2999631457 creator A5070424111 @default.
• W2999631457 date "2020-02-01" @default.
• W2999631457 modified "2023-10-11" @default.
• W2999631457 title "Safety and tolerability of adjunctive brivaracetam in epilepsy: In-depth pooled analysis" @default.
• W2999631457 cites W1502126985 @default.
• W2999631457 cites W1916788136 @default.
• W2999631457 cites W1970167469 @default.
• W2999631457 cites W1979558709 @default.
• W2999631457 cites W1981401201 @default.
• W2999631457 cites W1992028227 @default.
• W2999631457 cites W2025490080 @default.
• W2999631457 cites W2037616672 @default.
• W2999631457 cites W2040009475 @default.
• W2999631457 cites W2051013481 @default.
• W2999631457 cites W2061081161 @default.
• W2999631457 cites W2095271866 @default.
• W2999631457 cites W2099690974 @default.
• W2999631457 cites W2119181594 @default.
• W2999631457 cites W2123304989 @default.
• W2999631457 cites W2134247911 @default.
• W2999631457 cites W2140914231 @default.
• W2999631457 cites W2152165282 @default.
• W2999631457 cites W2160043884 @default.
• W2999631457 cites W2168143783 @default.
• W2999631457 cites W2284268250 @default.
• W2999631457 cites W2394919271 @default.
• W2999631457 cites W2419659369 @default.
• W2999631457 cites W2471268248 @default.
• W2999631457 cites W2472978162 @default.
• W2999631457 cites W2498582720 @default.
• W2999631457 cites W2510367931 @default.
• W2999631457 cites W2518276265 @default.
• W2999631457 cites W2562398824 @default.
• W2999631457 cites W2596918074 @default.
• W2999631457 cites W2613020156 @default.
• W2999631457 cites W2769836889 @default.
• W2999631457 cites W4247796277 @default.
• W2999631457 doi "https://doi.org/10.1016/j.yebeh.2019.106864" @default.
• W2999631457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31937513" @default.
• W2999631457 hasPublicationYear "2020" @default.
• W2999631457 type Work @default.
• W2999631457 sameAs 2999631457 @default.
• W2999631457 citedByCount "25" @default.
• W2999631457 countsByYear W29996314572020 @default.
• W2999631457 countsByYear W29996314572021 @default.
• W2999631457 countsByYear W29996314572022 @default.
• W2999631457 countsByYear W29996314572023 @default.
• W2999631457 crossrefType "journal-article" @default.
• W2999631457 hasAuthorship W2999631457A5012345968 @default.
• W2999631457 hasAuthorship W2999631457A5027558784 @default.
• W2999631457 hasAuthorship W2999631457A5030901765 @default.
• W2999631457 hasAuthorship W2999631457A5059712623 @default.
• W2999631457 hasAuthorship W2999631457A5070424111 @default.
• W2999631457 hasBestOaLocation W29996314571 @default.
• W2999631457 hasConcept C118552586 @default.
• W2999631457 hasConcept C120665830 @default.
• W2999631457 hasConcept C121332964 @default.
• W2999631457 hasConcept C126322002 @default.
• W2999631457 hasConcept C142724271 @default.
• W2999631457 hasConcept C197934379 @default.
• W2999631457 hasConcept C204787440 @default.
• W2999631457 hasConcept C27081682 @default.
• W2999631457 hasConcept C2778186239 @default.
• W2999631457 hasConcept C2778375690 @default.
• W2999631457 hasConcept C2779034229 @default.
• W2999631457 hasConcept C3018162438 @default.
• W2999631457 hasConcept C42219234 @default.
• W2999631457 hasConcept C535046627 @default.
• W2999631457 hasConcept C61511704 @default.
• W2999631457 hasConcept C71924100 @default.
• W2999631457 hasConceptScore W2999631457C118552586 @default.
• W2999631457 hasConceptScore W2999631457C120665830 @default.
• W2999631457 hasConceptScore W2999631457C121332964 @default.
• W2999631457 hasConceptScore W2999631457C126322002 @default.
• W2999631457 hasConceptScore W2999631457C142724271 @default.
• W2999631457 hasConceptScore W2999631457C197934379 @default.
• W2999631457 hasConceptScore W2999631457C204787440 @default.
• W2999631457 hasConceptScore W2999631457C27081682 @default.
• W2999631457 hasConceptScore W2999631457C2778186239 @default.
• W2999631457 hasConceptScore W2999631457C2778375690 @default.
• W2999631457 hasConceptScore W2999631457C2779034229 @default.
• W2999631457 hasConceptScore W2999631457C3018162438 @default.
• W2999631457 hasConceptScore W2999631457C42219234 @default.
• W2999631457 hasConceptScore W2999631457C535046627 @default.
• W2999631457 hasConceptScore W2999631457C61511704 @default.
• W2999631457 hasConceptScore W2999631457C71924100 @default.
• W2999631457 hasFunder F4320312574 @default.
• W2999631457 hasLocation W29996314571 @default.
• W2999631457 hasLocation W29996314572 @default.
• W2999631457 hasOpenAccess W2999631457 @default.
• W2999631457 hasPrimaryLocation W29996314571 @default.
• W2999631457 hasRelatedWork W1989429426 @default.

• next